effects of agvhd and cgvhd on survival rate in patients with acute myeloid leukemia after allogeneic stem cell transplantation.

نویسندگان

shabnam shokouhi department of epidemiology, faculty of public health, ilam university of medical sciences, ilam, iran ; psychosocial injuries research center, ilam university of medical sciences, ilam, iran.

sarah bray discipline of medicine, faculty of health sciences, university of adelaide, adelaide, south australia, australia ; department of hematology/oncology, basil hetzel institute for translational health research, the queen elizabeth hospital, woodville, south australia, australia.

salar bakhtiyari department of clinical biochemistry, faculty of medicine, ilam university of medical sciences, ilam, iran.

kourosh sayehmiri psychosocial injuries research center, ilam university of medical sciences, ilam, iran.

چکیده

background: allogeneic hematopoietic stem cell transplantation (hsct) is a curative treatment option for many patients with acute myeloid leukemia (aml); however, it can lead to complications of graft-versus-host-disease (gvhd) which can affect the quality of life and overall survival. the aim of this study was to assess the effects of both acute and chronic gvhd on survival rate in patients with aml who received hsct. subjects and methods: in a longitudinal study, 587 patients with aml who underwent bone marrow transplantation in tehran-iran between1991 and 2011 were recruited. all patient records were analyzed for the occurrence of adverse events including acute and chronic gvhd and leukemia relapse. data were analyzed using log-rank, kaplan-meier, univariate and multivariate cox regression models. results: the five-year overall survival (os) was found to be 71.9% (95% ci: 67.40-76.41). also there was a significant relationship between cgvhd and os (p=0.001, hr = 0.476, 95%). hazard of death in these patients was less than those who did not experience an occurrence of cgvhd and agvhd (hr= 0.629, p= 0.078). a significant relationship between cgvhd and relapse was observed (p< 0.001) indicating that patients who developed cgvhd experienced a better survival rate. a significant relationship was also found between overall survival and agvhd grade (p< 0.001). hazard of death (hd) for cgvhd and relapse variables were estimated to be 0.554 and 3.869. discussion: this study is one of the largest studies (regarding the number of participants) done to date in the middle east with quite a long duration (20 years). cgvhd appears to have a positive influence on survival rate in patients with aml who received hsct. it is recommended that further studies investigate the underlying reason or mechanisms behind this.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation

BACKGROUND Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a curative treatment option for many patients with Acute Myeloid Leukemia (AML); however, it can lead to complications of Graft-Versus-Host-Disease (GVHD) which can affect the quality of life and overall survival. The aim of this study was to assess the effects of both acute and chronic GVHD on survival rate in patients wit...

متن کامل

تأثیر GVHD مزمن بر بقا بیماران لوسمی میلوئیدی حاد پس از پیوند سلول‌های بنیادی خون محیطی از خواهر یا برادر با HLA مشابه بدون تخلیه سلول T

Background : Graft versus host disease (GVHD) is among major complications of allogeneic hematopoietic stem cells transplantation, and also is an important factor affecting the outcome of transplantation. An increased incidence of GVHD has been suggested following allogeneic peripheral blood stem cells (PBSC) transplantation, however, how this affects survival is not yet well clear. In this stu...

متن کامل

allogeneic stem cell transplantation outcome in acute lymphoblastic leukemia patients

introduction: despite achievement to complete remission (cr) with current treatments and new multiple chemotherapeutic agents in acute lymphoblastic leukemia (all) patients, the majority of them still relapse during long-term follow-up. the use of post- remission therapy will reduce early relapse in these cases, but the best option is still debatable. patients and methods: in this retrospective...

متن کامل

Allogeneic stem cell transplantation in acute myeloid leukemia

Allogeneic hematopoietic stem cell transplantation (alloSCT) has been established as a powerful treatment modality in acute myeloid leukemia (AML) in first or subsequent remission. Although alloSCT effectively prevents relapse, non-relapse mortality (NRM) associated with the procedure may counterbalance that beneficial effect. As a result, alloSCT generally is restricted to patients with a rela...

متن کامل

Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation.

We analyzed the frequency of neoplastic meningitis in patients with acute myeloid leukemia prior to allogeneic hematopoietic stem cell transplantation at our institution. Between 1996 and 2009, cerebrospinal fluid samples of 204 adult patients were examined during pre-transplant work-up for cell counts and, if abnormal, morphologically. We found blasts in cerebrospinal fluid samples of 17 patie...

متن کامل

Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia

Background: &nbsp;Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۹، شماره ۳، صفحات ۱۱۲-۱۲۱

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023